Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| EAGLE BULK S | EGLE | 3.67% |
| UNIVL TRUCKL | UACL | 2.74% |
| PDI INC | PDII | 2.60% |
| A M R CP | AAMRQ | 1.79% |
| CGG VERITAS | CGG | 1.67% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Recently, Accenture plc (ACN - Snapshot Report) won two new deals from the “New York University Langone Medical Center” (NYU Langone) and the European Commission Directorate General for Home Affairs.
The company won a contract from NYU Langone to support its ICD-10 implementation program by using clinical processes. This will help recognize and reduce financial losses.
As per the latest agreement, the consulting company will aid NYU Langone to shift all the areas related to ICD-10 mandates, associated with the implementation of computer-assisted coding software. This in turn will help the latter administer online training and support the entire healthcare network, which includes help taken by the physicians. This apart, Accenture is expected to help in dual coding up to 12 months prior to the federally mandated ICD-10 deadline.
The company has also won a deal from the European Commission Directorate General for Home Affairs. The commission has awarded the contract jointly to Accenture, Morpho (Safran) and Hewlett-Packard Company (HPQ - Analyst Report) to maintain the technology setup of the European Visa Information System (VIS). The contract has a total period of three years, with an extension period of one year and a maximum value of €70 million.
Over the past decade, Accenture won several deals across different business segments. However, the company is now focused on deals with better margins. A series of contract wins at the beginning of 2013, is certainly a good start for Accenture. Apart from Accenture, IBM (IBM - Analyst Report) and Dell Inc. (DELL - Analyst Report) have also started aggressive marketing to grab a chunk of the healthcare market as well as other software or allied businesses.
Accenture has increased focus on the healthcare industry, which is growing rapidly and offering different employment and business opportunities. A recently-published report from the Bureau of Labor Statistics suggests that December was a huge hiring month for healthcare, with the addition of 45,000 healthcare jobs.
We are optimistic about Accenture’s broad industry exposure as this could mitigate the weakness in government spending. Currently, Accenture has a Zacks Rank #4 (Sell).
Read the full Snapshot Report on ACN
Read the full Analyst Report on HPQ
Read the full Analyst Report on IBM
Read the full Analyst Report on DELL